Cargando…
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
Psoriatic involvement in areas of the body such as nails, palms and soles (palmoplantar), and scalp is associated with dramatically negative effects on quality of life relative to involvement elsewhere in the body. Although numerous evidence-based studies demonstrate the efficacy of biologics for ov...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209590/ https://www.ncbi.nlm.nih.gov/pubmed/35672564 http://dx.doi.org/10.1007/s13555-022-00746-6 |
_version_ | 1784729982445027328 |
---|---|
author | Menter, Alan Bhutani, Tina Ehst, Benjamin Elewski, Boni Jacobson, Abby |
author_facet | Menter, Alan Bhutani, Tina Ehst, Benjamin Elewski, Boni Jacobson, Abby |
author_sort | Menter, Alan |
collection | PubMed |
description | Psoriatic involvement in areas of the body such as nails, palms and soles (palmoplantar), and scalp is associated with dramatically negative effects on quality of life relative to involvement elsewhere in the body. Although numerous evidence-based studies demonstrate the efficacy of biologics for overall skin clearance in moderate-to-severe plaque psoriasis (including tumor necrosis factor α [TNFα] inhibitors and interleukin [IL]-17A, IL-12/IL-23, IL-23, IL-17F, and IL-17A/F inhibitors), large, randomized, placebo-controlled clinical studies of psoriasis with nail, palmoplantar, and scalp involvement are needed to better inform decision-making in clinical practice. Moreover, biologic failure caused by drug ineffectiveness is a common occurrence in patients who do not respond, lose response, or are intolerant to treatment. Brodalumab is a fully human IL-17 receptor A antagonist that demonstrates high rates of skin clearance among the latest generation of biologic therapies for treatment of moderate-to-severe psoriasis. This review summarizes current literature on the efficacy of brodalumab and other therapies in difficult-to-treat psoriasis including psoriasis in difficult-to-treat locations (such as psoriasis with nail, palmoplantar, or scalp involvement) and psoriasis in patients whose disease did not respond to other biologics. |
format | Online Article Text |
id | pubmed-9209590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-92095902022-06-22 Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis Menter, Alan Bhutani, Tina Ehst, Benjamin Elewski, Boni Jacobson, Abby Dermatol Ther (Heidelb) Review Psoriatic involvement in areas of the body such as nails, palms and soles (palmoplantar), and scalp is associated with dramatically negative effects on quality of life relative to involvement elsewhere in the body. Although numerous evidence-based studies demonstrate the efficacy of biologics for overall skin clearance in moderate-to-severe plaque psoriasis (including tumor necrosis factor α [TNFα] inhibitors and interleukin [IL]-17A, IL-12/IL-23, IL-23, IL-17F, and IL-17A/F inhibitors), large, randomized, placebo-controlled clinical studies of psoriasis with nail, palmoplantar, and scalp involvement are needed to better inform decision-making in clinical practice. Moreover, biologic failure caused by drug ineffectiveness is a common occurrence in patients who do not respond, lose response, or are intolerant to treatment. Brodalumab is a fully human IL-17 receptor A antagonist that demonstrates high rates of skin clearance among the latest generation of biologic therapies for treatment of moderate-to-severe psoriasis. This review summarizes current literature on the efficacy of brodalumab and other therapies in difficult-to-treat psoriasis including psoriasis in difficult-to-treat locations (such as psoriasis with nail, palmoplantar, or scalp involvement) and psoriasis in patients whose disease did not respond to other biologics. Springer Healthcare 2022-06-07 /pmc/articles/PMC9209590/ /pubmed/35672564 http://dx.doi.org/10.1007/s13555-022-00746-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Menter, Alan Bhutani, Tina Ehst, Benjamin Elewski, Boni Jacobson, Abby Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis |
title | Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis |
title_full | Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis |
title_fullStr | Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis |
title_full_unstemmed | Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis |
title_short | Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis |
title_sort | narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209590/ https://www.ncbi.nlm.nih.gov/pubmed/35672564 http://dx.doi.org/10.1007/s13555-022-00746-6 |
work_keys_str_mv | AT menteralan narrativereviewoftheemergingtherapeuticroleofbrodalumabindifficulttotreatpsoriasis AT bhutanitina narrativereviewoftheemergingtherapeuticroleofbrodalumabindifficulttotreatpsoriasis AT ehstbenjamin narrativereviewoftheemergingtherapeuticroleofbrodalumabindifficulttotreatpsoriasis AT elewskiboni narrativereviewoftheemergingtherapeuticroleofbrodalumabindifficulttotreatpsoriasis AT jacobsonabby narrativereviewoftheemergingtherapeuticroleofbrodalumabindifficulttotreatpsoriasis |